Introduction {#Sec1}
============

The diagnosis of breast cancer is a devastating blow for women and is associated with depression, anxiety, and a range of other psychological problems, such as self-blame and negative perception of body-image \[[@CR1]--[@CR5]\]. Newly diagnosed metastatic breast cancer (MBC) is also associated with high levels of psychological morbidity, particularly for younger women \[[@CR6]\]. Prevention of relapse is a long-term therapeutic imperative, but the impact of therapy on quality of life (QOL) also needs to be taken into consideration when planning treatment strategies.

All therapeutic modalities for early breast cancer (mastectomy or lumpectomy, radiation, chemotherapy, antibody therapy and endocrine therapy) can have a significant impact on patients' QOL both in the short-term and in the transition period from primary treatment to long-term survivorship \[[@CR7]--[@CR9]\]. Receiving good quality information about prognosis, treatment options, side effects, and risks of breast cancer recurrence is, therefore, important for patients diagnosed with breast cancer \[[@CR10]--[@CR13]\].

The third-generation aromatase inhibitor (AI) letrozole was introduced a decade ago, but at that time, a limited amount of information on breast cancer and its treatment was available to patients. Since then, the international oncology community has made major advances in its knowledge about breast cancer biology, the individualization of treatment options, and communication with patients. Greater understanding of genetics and breast cancer risk has improved approaches for counseling individuals about their susceptibility \[[@CR14]\]. In women who develop breast cancer, the individualization of treatment is becoming more sophisticated through the use of biomarkers as prognostic and predictive factors. These include human epidermal growth factor receptor (HER) 2 \[[@CR15], [@CR16]\], urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 \[[@CR17], [@CR18]\], mRNA expression patterns \[[@CR19], [@CR20]\], and, more recently, genetic profiling techniques \[[@CR21], [@CR22]\]. Individualizing treatment is also made easier by the ability to more accurately determine the patient's risk factors and prognosis; for example, by using the Adjuvant! Online program \[[@CR23]--[@CR25]\]. Recognizing breast cancer overtreatment has also contributed to tailoring treatment according to individual risk \[[@CR26]--[@CR30]\]. Oncology teams have facilitated patient involvement in selecting the most appropriate therapy \[[@CR24], [@CR31], [@CR32]\] and have improved the provision of patient information, support, and counseling \[[@CR33], [@CR34]\].

At the same time, patients began to organize effectively and expand their access to knowledge of new drugs and treatment paradigms \[[@CR35]--[@CR37]\]. Patients have learned to be informed so that they can have constructive dialogues with their doctors and feel they understand and contribute to treatment decisions \[[@CR38]--[@CR42]\]. Patients who take an active role in the decision-making process perceive that they have a treatment choice, in contrast to those who prefer a shared or passive role \[[@CR43]\]. They know they cannot be told at any time during the course of their disease that they are or are not cured; they recognize that breast cancer is a chronic illness. Patients are now empowered with hope and the knowledge that breast cancer can be managed. Moreover, increased survival rates have prompted greater interest in the QOL of breast cancer survivors \[[@CR44]--[@CR46]\].

Better education and improved access to screening has resulted in fewer patients being diagnosed with advanced breast cancer at their first presentation, and consequently, mortality has decreased \[[@CR29], [@CR47]--[@CR49]\]. In addition, more effective adjuvant therapy with third-generation AIs has significantly decreased the risk of recurrence as compared with the previous standard of care based on tamoxifen \[[@CR50]--[@CR53]\]. However, there remains a long-term risk of breast cancer recurrence over time \[[@CR54], [@CR55]\]. Hormone receptor-positive (HR+) breast cancer is particularly challenging because of the persistent risk of recurrence with this chronic "smoldering" disease. The Early Breast Cancer Trialists Collaborative Group meta-analysis showed that in untreated women with the same nodal status, the breast cancer death rate is greater for patients with estrogen receptor-negative (ER−) versus ER+ tumors in the first 5--6 years, but substantially lower for ER− versus ER+ tumors over the next 10 years \[[@CR56]\]. Similarly, Saphner reported that beyond 5 years, the risk of recurrence was higher for patients with HR+ tumors than for those with HR− tumors (*P* = 0.00002) \[[@CR54]\].

Patients may experience stress after medical therapy is ended because they feel they have lost a safety net \[[@CR57], [@CR58]\]. This fear is understandable and justifiable in view of the persistent risk of recurrence for HR+ breast cancer. An analysis of the MA.17 trial of extended adjuvant therapy recently showed an increasing risk of disease recurrence over time in patients treated with placebo after discontinuing tamoxifen \[[@CR59]\]. Not surprisingly, therefore, patients may be willing to receive long-term therapy (extended adjuvant) to prevent recurrence provided that the benefits outweigh the risks and QOL is maintained \[[@CR60]\]. Patients will try to tolerate treatment-related adverse events if there is the prospect of achieving a "cure," i.e. remaining free of relapse during their lifetime.

Tamoxifen was the mainstay of breast cancer therapy, but its time-dependent efficacy and serious adverse events created a need for new therapies \[[@CR61]--[@CR63]\]. The suppression of estrogen was shown to be greater and more selective with third-generation AIs than with first- and second-generation compounds \[[@CR64]\], and this has resulted in better clinical outcomes and improved tolerability \[[@CR65]\]. This review examines the clinical use of the third-generation AI letrozole from the patient's perspective and assesses how it has improved treatment outcomes across the breast cancer continuum, including advanced or MBC, extended and initial adjuvant therapy, and neoadjuvant therapy.

Metastatic setting {#Sec2}
==================

Endocrine therapy is the first-choice treatment for women with HR+ breast cancer without acute life-threatening symptoms and should be administered for as long as possible before switching to cytotoxic regimens. Endocrine therapy is preferred to cytotoxic chemotherapy because of its more favorable safety profile \[[@CR66]\]. Thus, extending the time to the initiation of chemotherapy is important with endocrine therapy, because a considerable proportion of patients who progress to chemotherapy will experience toxic side effects without gaining benefit \[[@CR67]\]. The most common acute side effects of chemotherapy, such as leukopenia, alopecia, and nausea and vomiting, are significantly increased in women receiving combination regimens compared with single agents \[[@CR68]\]. Chemotherapy can also adversely affect certain aspects of QOL, notably increasing fatigue \[[@CR69]\], and some regimens may be associated with severe or life-threatening complications such as cardiac failure \[[@CR70]\]. A meta-analysis to review the evidence and determine whether chemotherapy or endocrine therapy has the most beneficial effect on treatment outcomes (survival, response rate, toxicity, and QOL) concluded that in women with HR+ MBC, a policy of treating first with endocrine therapy rather than chemotherapy is recommended except in the presence of rapidly progressive disease \[[@CR71]\].

Prior to the introduction of third-generation AIs, postmenopausal patients with hormone-responsive MBC had few endocrine therapy options other than tamoxifen \[[@CR62]\]. Second-line endocrine agents were limited by safety concerns, including weight gain or the risk of thromboembolism with megestrol acetate \[[@CR72], [@CR73]\] and cardiovascular toxicity with aminoglutethimide \[[@CR65]\]. Randomized controlled trials demonstrated that letrozole is better tolerated and more effective than these second-line endocrine agents \[[@CR65], [@CR72], [@CR73]\]. Furthermore, letrozole has also demonstrated superior early survival compared with tamoxifen as first-line therapy in postmenopausal patients with MBC \[[@CR74]\]. Importantly, longer time to disease progression with letrozole versus tamoxifen was achieved without increased time with adverse events and resulted in more quality-adjusted survival for patients on letrozole \[[@CR75]\]. Maintaining functional ability is an important goal for patients treated in this setting. A subanalysis by different sites of metastatic lesion and Karnofsky Performance Scores also showed the superiority of letrozole compared with tamoxifen in patients with nonvisceral metastases, with visceral metastases without liver involvement, and with liver metastases \[[@CR76]\]. From the patient's perspective, it is important to receive the most effective therapy first-line; therefore, letrozole represents a more attractive option than tamoxifen for postmenopausal women.

Pharmacologic and clinical differences exist between third-generation inhibitors and should be considered in the selection of the most appropriate endocrine therapy \[[@CR64], [@CR77]\]. Data from a small randomized crossover trial in 72 postmenopausal women with HR+ MBC showed that overall QOL was significantly better with letrozole than with anastrozole (*P* = 0.002 for mean total Functional Assessment of Cancer Treatment-endocrine symptoms) \[[@CR78]\]. Furthermore, letrozole was significantly better tolerated overall than anastrozole. Less nausea, fewer hot flashes, and less abdominal discomfort resulted in almost twice as many patients preferring letrozole to anastrozole \[[@CR78]\].

While letrozole is an appropriate first-line therapy for the majority of patients with hormone-responsive MBC, a small subset of patients with HR+ HER2+ tumors have high-risk disease and are candidates for early treatment with chemotherapy plus the anti-HER2 monoclonal antibody trastuzumab \[[@CR79]\]. A meta-analysis of 12 studies involving 2,379 patients with MBC demonstrated that HER2+ tumors are less responsive than HER2− tumors to endocrine treatment (overall relative risk 1.42; 95% confidence interval, 1.32--1.52; *P* \< 0.00001) \[[@CR80]\]. Evidence from preclinical models suggests that trastuzumab may overcome relative resistance to endocrine therapy \[[@CR81]\], providing the rationale for combining anti-HER2 and endocrine therapies in the clinical setting. Recently, the first published results of an AI in combination with an anti-HER2 antibody (i.e. trastuzumab) show that the combination demonstrated durable responses for at least 1 year in 25% of patients \[[@CR82]\]. Preliminary results from a phase 3 trial (TrAstuzumab in Dual HER2 ER-positive Metastatic breast cancer) demonstrated that the combination of trastuzumab with an AI (anastrozole) was more effective than anastrozole alone in postmenopausal patients with HR+ HER2+ MBC \[[@CR83]\]. Another phase 3 trial, which is enrolling more than 1,200 patients in this setting and has just finished recruitment, is investigating letrozole in combination with lapatinib, a dual inhibitor of HER2 and HER1 tyrosine kinases \[[@CR84]\]. The strategy of combining letrozole with trastuzumab (as investigated in the evaluation of Letrozole combined with Trastuzumab trial), or another HER2-directed therapy, may allow patients with HR+, HER2+ tumors to safely delay the initiation of cytotoxic chemotherapy.

Adjuvant therapy {#Sec3}
================

Patients receiving adjuvant therapy expect their treatment to prevent breast cancer recurrence and offer the prospect of cure. However, even modest gains in survival are sufficient to make adjuvant endocrine treatment worthwhile for premenopausal women with early-stage breast cancer \[[@CR85]\]. This benefit threshold also appears to apply to women with a higher risk of recurrence for whom adjuvant chemotherapy is indicated \[[@CR86]\]. Adjuvant therapy should be tailored to suit the needs of individual patients based on their clinical risk factors, attitudes, and personal life circumstances \[[@CR25]\]. However, it is important to recognize that individual preferences cannot always be fully explained on the basis of treatment-related determinants and patient or clinical characteristics \[[@CR87]\].

The Anastrozole versus Letrozole: Investigation into Quality of Life study compared the effects of anastrozole and letrozole on estrogen levels, QOL, lipids, and bone health \[[@CR88]\]. A total of 185 postmenopausal women with invasive breast cancer were randomized to receive adjuvant therapy with either 12 weeks of letrozole followed by 12 weeks of anastrozole or vice versa. Of the patients who have completed the 12 weeks of treatment (*n* = 146), 50 (34%) had a preference for neither drug, 50 (34%) preferred anastrozole, and 46 (32%) preferred letrozole. Both estradiol (E2) and estrone sulfate levels (E1S) were significantly lower on letrozole than on anastrozole (*P* \< 0.000001). Thus, 2.5 mg of letrozole reduces circulating E2 and E1S levels to a significantly greater degree than 1 mg of anastrozole, with no significant difference in patient preference. The greater suppression of estradiol levels might translate into improved clinical efficacy, although further studies, such as the ongoing Femara Anastrozole Clinical Evaluation trial, are required to confirm these findings.

Patients with HR+ tumors need to consider the prospect of life-long adjuvant therapy in view of the persistent risk of disease recurrence \[[@CR54], [@CR56], [@CR89]\]. Following the introduction of third-generation AIs, there is much greater choice in endocrine therapy. The challenge for physicians is to select the most appropriate strategy to suit individual patient circumstances. Letrozole first entered the adjuvant setting as a treatment option for patients completing 5 years of tamoxifen \[[@CR90]\] and has demonstrated clinical superiority over tamoxifen as initial adjuvant therapy \[[@CR51]\] and neoadjuvant therapy \[[@CR91]\].

Neoadjuvant therapy {#Sec4}
===================

Neoadjuvant endocrine therapy with letrozole is an attractive option for some postmenopausal patients with HR+ early breast cancer \[[@CR92]\], including elderly patients who are unable or unwilling to undergo chemotherapy or surgery, and patients with locally advanced HR+ tumors who wish to have breast-conserving surgery but are not suited for preoperative chemotherapy \[[@CR91], [@CR93]\]. In a randomized controlled trial, letrozole demonstrated a superior overall objective response rate and rate of breast-conserving surgery compared with tamoxifen as neoadjuvant therapy \[[@CR91]\]. Currently, letrozole is the only AI approved in the neoadjuvant setting (in the United Kingdom and 16 other countries worldwide). It provides a reasonable therapeutic alternative to preoperative chemotherapy in postmenopausal women with HR+ disease in clinical situations where the low toxicity of the regimen is considered an advantage, e.g. in women older than 70 years \[[@CR91]\]. However, patients need to be aware that a longer course of therapy may be required to achieve an objective response than is the case with neoadjuvant chemotherapy \[[@CR94]\]. In one study, neoadjuvant letrozole was safely given over 12 months to postmenopausal women with large operable or locally advanced HR+ breast cancers \[[@CR94]\]. A longer treatment course may suit some patients and give them more time to consider their options for surgery, radiotherapy, and chemotherapy.

Neoadjuvant therapy with letrozole could be considered a sensitivity test of endocrine therapy that might be incorporated into strategies to individualize adjuvant treatment according to response \[[@CR95]\]. This would provide reassurance to patients that they will be receiving an adjuvant endocrine therapy that has shown activity against their tumor. Objective assessment of the antitumor activity of neoadjuvant letrozole can be made on the basis of response rate and by analysis of predictive biomarkers. In one study, neoadjuvant letrozole was found to inhibit tumor proliferation (determined by the biomarker Ki67) more effectively than tamoxifen \[[@CR95]\]. Letrozole was effective independently of HER2 expression status, although the greatest difference between letrozole and tamoxifen was seen in tumors that were HR+ and HER1/2+. Recent evidence has suggested that HER2+ tumors can continue to proliferate despite neoadjuvant letrozole or tamoxifen treatment, which could imply therapeutic resistance that may manifest later in the clinical course of the disease \[[@CR96]\].

Biomarker studies may also reveal differences between AIs. In a randomized comparative trial, letrozole and anastrozole significantly reduced proliferation in HR+, HER2+ or HER2− tumors \[[@CR97]\]. Decreased proliferation was seen at all Allred ER expression levels with both agents, but only letrozole showed a significant effect in the lower ER cases. In addition, more cases showed a reduction in progesterone receptor (PgR) expression following letrozole than anastrozole \[[@CR97]\]. Another study showed evidence of a decrease in HER2 expression after neoadjuvant treatment with letrozole \[[@CR98]\].

Although complex, biomarkers may become increasingly important from a patient's perspective, because they can help to improve the individualization of treatment. Furthermore, biomarkers may be useful to predict the risk of resistance to endocrine therapy and the need to consider alternative approaches in the future, such as combination therapies or cytotoxic chemotherapy. Knowing what to expect next is important for patients. However, further work is necessary to validate the use of clinical markers and biomarkers in the neoadjuvant setting as surrogate end points for long-term outcomes \[[@CR96]\].

Early adjuvant therapy {#Sec5}
======================

Tamoxifen was the gold standard endocrine therapy for all women with HR+ breast cancer until recent results from large randomized trials challenged this paradigm for postmenopausal women \[[@CR50], [@CR51], [@CR99]\]. Oncologists and patients now face an important choice when selecting adjuvant endocrine treatment \[[@CR66], [@CR100]\], whether to start with the most potent endocrine therapy (an AI) upfront or to start with tamoxifen and switch to an AI inhibitor after 2--5 years. The ongoing Breast International Group (BIG) 1-98 randomized trial is expected to provide more information on the benefits of switching to letrozole after 2--3 years on tamoxifen and will clarify which is the optimal strategy. The final results are expected to be released in 2008 \[[@CR51]\], but until then, the most appropriate endocrine therapy will need to be selected on the basis of currently available evidence. The MA.17 trial has already demonstrated that letrozole treatment is beneficial after 5 years of adjuvant tamoxifen \[[@CR90], [@CR101], [@CR102]\].

Patients will ideally wish to receive treatment that provides the greatest long-term efficacy with the lowest risk of adverse events. BIG 1-98 showed that letrozole was significantly more effective than tamoxifen as initial adjuvant endocrine therapy \[[@CR51]\]. Moreover, tamoxifen is perceived to be more toxic than AIs, largely because of well-publicized "scares" about increased risk of uterine cancer and thrombosis \[[@CR61], [@CR103]\]. These side effects and vaginal bleeding were reported for tamoxifen in BIG 1-98, whereas letrozole was associated with more skeletal events. The overall rate of cardiovascular events was not significantly different between the groups. Letrozole was also shown to be extremely well-tolerated in comparison with placebo in the MA.17 trial \[[@CR90], [@CR101]\]. With the exception of adverse events related to suppression of estrogen, there was no difference in adverse events (Table [1](#Tab1){ref-type="table"}). Table 1Safety profile of letrozole in comparison with placebo (A) and tamoxifen (B) reported in postmenopausal women with early breast cancerPlaceboAcute toxicities reportedTotal number (%), any grade^101^Letrozole (*n* = 2,572)Placebo (*n* = 2,577)Edema571 (22)542 (21)Hypertension130 (5)129 (5)Hot flushes1,486 (58)^a^1383 (54)Fatigue999 (39)998 (39)Sweating782 (30)760 (29)Anorexia142 (6)^a^110 (4)Constipation363 (14)382 (15)Diarrhea168 (7)176 (7)Nausea308 (12)314 (12)Vaginal bleeding145 (6)196 (8)^a^Infection without neutropenia124 (5)112 (4)Arthritis167 (6)137 (5)Hypercholesterolemia418 (16)411 (16)Dizziness458 (18)441 (17)Insomnia166 (6)135 (5)Depression143 (6)131 (5)Headache706 (27)685 (27)Arthralgia651 (25)^a^532 (21)Myalgia380 (15)^a^310 (12)Bone pain141 (5)149 (6)Dyspnea161 (6)163 (6)Alopecia126 (5)^a^89 (3)Vaginal dryness147 (6)129 (5)TamoxifenWorst grade adverse events recorded within first 28 daysTotal number (%), any grade^51^Letrozole (*n* = 3,975)Tamoxifen (*n* = 3,988)CVA or TIA39 (1.0)41 (1.0)Thromboembolic event61 (1.5)140 (3.5)^a^Cardiac event (IHD, CF)162 (4.1)153 (3.8)Other CV event19 (0.5)^a^8 (0.2)Vaginal bleeding132 (3.3)263 (6.6)Hot flushes1332 (33.5)1516 (38.0)^a^Night sweats554 (13.9)647 (16.2)^a^Fracture225 (5.7)^a^159 (4.0)Arthralgia806 (20.3)^a^491 (12.3)Myalgia254 (6.4)243 (6.1)*CV* cardiovascular, *CVA* cerebrovascular accident, *TIA* transient ischemic attack, *IHD* ischemic heart disease, *CF* cardiac failure^a^Significant difference

Based on the results from the BIG 1-98 and the Anastrozole and Tamoxifen Alone or in Combination (ATAC) trial, which compared upfront AIs with tamoxifen, it is clear that all postmenopausal women with HR+ breast cancer should be given the opportunity to receive adjuvant use of an AI, and this recommendation is now reflected in internationally recognized treatment guidelines \[[@CR66], [@CR100], [@CR104], [@CR105]\]. Patients with HR+ breast cancer considered eligible for adjuvant chemotherapy because of their increased risk for relapse should also be candidates for the most effective adjuvant endocrine strategy \[[@CR100]\]. Of note, the BIG 1-98 trial showed that adjuvant letrozole provides significant disease-free survival (DFS) benefits for patients at increased risk of recurrence, specifically patients with node-positive tumors, large primary tumors (\>2 cm), and recipients of chemotherapy and also demonstrated a significant reduction in the risk of distant recurrence, a well-known predictor of breast cancer death \[[@CR51]\]. Additional analyses of data from BIG 1-98 to determine the predictive value of centrally tested ER, PgR, and HER2 status on the response to letrozole and tamoxifen indicate that there is no difference in subgroups by ER/PR or HER2 status regarding the superiority of upfront letrozole versus tamoxifen \[[@CR106]\]. Low-risk patients with HR+ breast cancer who do not receive adjuvant chemotherapy are also candidates for AIs \[[@CR104]\] because of the persistent risk of relapse \[[@CR54], [@CR56]\].

While it is known that tamoxifen loses effectiveness after 5 years \[[@CR62], [@CR63]\], the optimal duration of initial therapy with an AI remains to be determined \[[@CR107]\]. The MA.17 randomized controlled trial of extended adjuvant endocrine therapy has already shown that letrozole treatment is beneficial after 5 years of tamoxifen in postmenopausal patients \[[@CR90], [@CR101]\], but there are no equivalent data on the use of tamoxifen after initial AI therapy in the adjuvant setting \[[@CR100]\]. Furthermore, the efficacy of switching to another AI in patients who discontinue treatment with letrozole is not known. Therefore, patients starting upfront therapy with letrozole will need reassurance that according to present knowledge, treatment can be continued for up to 5 years, and other options will be available down the line. In addition, patients will require information about the potential long-term impact of AIs on bone and the cardiovascular system \[[@CR107]\].

According to the current treatment guidelines \[[@CR66], [@CR100], [@CR104], [@CR105]\], patients already taking a course of adjuvant tamoxifen may wish to switch to anastrozole or exemestane, as these AIs have demonstrated efficacy in this setting \[[@CR52], [@CR108], [@CR109]\]. Although recent data have shown that this sequential adjuvant strategy is associated with a survival advantage \[[@CR53], [@CR110], [@CR111]\], it is important to note that these data were obtained from a selected population comprising patients at randomization who were disease-free after 2--3 years of tamoxifen. It is therefore not valid to make a direct comparison with an unselected population treated in trials of upfront AI therapy. The decision to switch endocrine therapy after 2--3 years, i.e. for a sequential tamoxifen--AI strategy, should be based on an individual's risk for recurrence, risk for osteoporosis, and ability to tolerate tamoxifen. Importantly, BIG 1-98 is expected to provide more information on the benefits of switching to letrozole after 2--3 years of tamoxifen, and will clarify whether upfront or sequential AI use is the optimal strategy. The final results will be released in 2008 \[[@CR51]\].

Extended adjuvant (including late extended adjuvant) therapy {#Sec6}
============================================================

Many patients fear breast cancer recurrence \[[@CR112]\] and are reassured by the "safety net" of continuing medical treatment and monitoring \[[@CR9]\]. The MA.17 trial showed that extended adjuvant therapy with letrozole gives patients the opportunity of retaining the safety net for at least 5 more years after adjuvant tamoxifen \[[@CR101]\], and these results led to its approval in this indication. Currently, letrozole is the only AI approved as an extended adjuvant therapy.

The final analysis of MA.17 after a median follow-up of 30 months showed letrozole significantly improved DFS (42% reduction in risk vs. placebo), distant DFS (40% reduction in risk vs. placebo) and, in node-positive patients, overall survival (39% reduction in risk vs. placebo) \[[@CR101]\]. A recent cohort analysis of the MA.17 trial data suggested that the longer patients are exposed to letrozole, the greater the benefit, at least out to 48 months \[[@CR59]\]. In addition, an extension to the MA.17 trial (MA.17 Re-randomization) is being conducted to determine the benefits of continuing letrozole for a further 5 years \[[@CR102]\].

When a planned interim analysis of MA.17 revealed a significant advantage for letrozole, the trial was unblinded and patients on placebo were given the option to switch to letrozole \[[@CR90]\]. In this non-randomized comparison, women from the placebo arm who elected to switch to letrozole also experienced an improvement in outcome when compared with those who elected to have no treatment \[[@CR102]\].

Recurrence risk persists beyond the completion of adjuvant therapy, even in patients at low risk of recurrence. One study shows that with systemic adjuvant therapy, patients with node-negative breast cancer have a ≥25% 10-year risk of relapse and a corresponding 10-year breast cancer death rate as high as ≥10%, depending on tumor grade and size \[[@CR113]\]. Thus, the proven efficacy of letrozole given after a tamoxifen-free period means that physicians need to discuss the option of restarting endocrine therapy with almost all patients. Physicians have to consider how best to address this topic with patients who are up to 2--3 years out beyond their initial 5 years of tamoxifen, i.e. about 5--8 years after their initial diagnosis. This will be a major communication challenge and create a dilemma for patients who may feel well and have put their breast cancer behind them.

Safety and compliance issues {#Sec7}
============================

The clinical benefits of AIs and tamoxifen are generally achieved without a major detrimental effect on overall QOL \[[@CR114]\]. Data from the MA.17 trial, which is the only large adjuvant trial comparing AI therapy not with tamoxifen but with placebo, showed that overall QOL was maintained during extended therapy with letrozole, and only a minority of patients experienced substantial changes in QOL, which were compatible with a reduction in estrogen synthesis \[[@CR115]\]. It is important to recognize that patients may attribute such changes to their treatment, whereas they could in fact be symptoms of menopause \[[@CR116]\]. However, side effects do occur, which not only affect patient adherence to endocrine therapy \[[@CR117]\] but can also lead to additional morbidity and even serious or life-threatening complications in a small minority of patients \[[@CR51], [@CR52], [@CR90], [@CR99], [@CR108], [@CR109]\].

The main safety concerns with long-term estrogen deprivation include potential effects on bone health, cardiac health, lipid profile, cognitive functioning, and sexual health \[[@CR100]\]. The MA.17 trial showed that letrozole is well-tolerated in comparison with placebo \[[@CR101]\], and BIG 1-98 showed that letrozole was better tolerated than tamoxifen \[[@CR51]\] (Table [1](#Tab1){ref-type="table"}). A recent patient-reported outcomes study in 104 tamoxifen-intolerant women found that switching to letrozole was associated with a significant reduction in hot flushes (*P* = 0.001) and significant improvements in QOL (*P* = 0.001) and mood (*P* = 0.04). Furthermore, when given the choice of continuing therapy, 66% of women indicated that they preferred to remain on letrozole, while only 24% preferred to go back to tamoxifen \[[@CR118]\].

Despite an increase in newly diagnosed osteoporosis with AIs, no significant difference in clinical fracture rate was seen between letrozole and placebo \[[@CR101]\]. A companion study to MA.17 showed that there was only a modest increase in bone resorption and reduction in bone mineral density (BMD) in the spine and hip with letrozole compared with placebo \[[@CR119]\]. Consequently, patients should be made aware of the risk of osteoporosis and given advice on lifestyle measures (e.g. exercise, diet, vitamins) to reduce risk. A baseline BMD measurement should be obtained for all patients before starting therapy with an AI. BMD should then be measured annually, and patients at high risk of osteoporosis should be considered for prophylactic use of a bisphosphonate \[[@CR120], [@CR121]\]. However, recent data from ATAC may be reassuring for patients facing upfront AI therapy, since they indicate that women with normal initial BMD did not develop osteoporosis during a 5-year AI treatment \[[@CR122]\].

Letrozole has been associated with an increase in arthralgia compared with placebo or tamoxifen, and myalgia compared with placebo \[[@CR51], [@CR101]\]. Arthralgia and joint pain can be bothersome and may lead to impaired mobility. Patients need to be advised that constant exercising of the joints will alleviate this adverse event and that use of nonsteroidal anti-inflammatory drugs over a certain period of time may be helpful. Moreover, these complaints seem to be most frequent in the beginning of AI therapy \[[@CR123]\].

Another potential consequence of endocrine therapy is a detrimental effect on sexual health \[[@CR115], [@CR116]\]. Vaginal dryness is a consequence of menopause and treatments that cause menopausal symptoms, and has an important bearing on sexual health and well-being of breast cancer survivors \[[@CR124]\]. Vaginal dryness can be a significant problem that can interfere with the stability of relationships \[[@CR125]\], and patients need to receive counseling with regard to this issue \[[@CR126]\]. It has been shown that clinical assessment and an active intervention program for menopausal symptom management in breast cancer survivors can lead to an improvement in sexual functioning \[[@CR127]\]. A recent report demonstrated that the use of local estradiol therapy may cause elevation of serum estradiol and may therefore be contraindicated in postmenopausal women on AI therapy \[[@CR128]\]. So far, such data do not exist for estradiol-containing compounds; thus, local estradiol treatment may be indicated in individual cases. Androgen treatment may also improve sexual well-being in postmenopausal women \[[@CR129]\], yet the oncological safety of this approach has not been validated in patients receiving AI therapy. Of note, the incidence of vaginal dryness in the MA.17 trial was similar in the letrozole and placebo groups (Table [1](#Tab1){ref-type="table"}) \[[@CR101]\].

Differential effects on lipid profiles and cardiac risk have been reported between tamoxifen and AIs \[[@CR51], [@CR130], [@CR131]\], but data from the Letrozole, Exemestane, and Anastrozole Pharmacodynamics trial, directly comparing the effects of anastrozole, letrozole, and exemestane on lipid profiles in healthy postmenopausal women, suggest that the steroidal and nonsteroidal inhibitors have a similar impact on lipid profiles \[[@CR132]\]. On the basis of evidence from large randomized trials, when comparing letrozole with tamoxifen or placebo, it appears that letrozole does not have clinically relevant adverse effects on lipids or cardiac risk during long-term adjuvant therapy, although further assessment is warranted \[[@CR51], [@CR101], [@CR133]\].

While letrozole is well-tolerated, and any side effects that do occur can be managed, it is essential that patients are motivated to stay on therapy. This can be a particular challenge in the extended adjuvant setting. Thus, as patients now face the prospect of receiving endocrine therapy for 10 years or more, it is important to consider the overall life-long benefits and risks from the individual's perspective. A low burden of adverse events and maintenance of QOL is important in maintaining adherence to long-term treatment \[[@CR60]\]. In the MA.17 trial, the rate of patients choosing to discontinue therapy during the first year was similar for letrozole (*n* = 256/2,575) and placebo (*n* = 254/2,582) \[[@CR90]\]. Letrozole is ingested orally and can be safely and conveniently taken at home. Physician contact with oral endocrine therapy can be much less frequent than, for example, with orally active chemotherapy where regular blood tests, side-effect monitoring, and resulting dose modifications make frequent physician contact mandatory. Patients with breast cancer prefer oral cancer therapy providing that it does not compromise treatment efficacy \[[@CR134]\].

Conclusions {#Sec8}
===========

Patients with breast cancer face bewildering choices at a time when they are experiencing highly stressful circumstances. Moreover, many of these women are not well-informed and thus are not able to take part in treatment decisions. The Gathering Information on Adjuvant Endocrine therapy initiative decided to delineate women's knowledge and experience of adjuvant endocrine therapy. Results thus far indicate that only 22% of patients were fully or highly involved in the decision to start adjuvant endocrine therapy \[[@CR135], [@CR136]\]. Many of the women who took part in the survey were not satisfied with the degree to which they were involved in treatment decision-making, and women 60 years or older had the lowest levels of involvement \[[@CR135], [@CR136]\]. The results from this survey show that information provided to patients about adjuvant endocrine therapy is suboptimal and indicate the need for programs to raise patient awareness. The medical community has a responsibility to help patients understand their prospects for survival and make the right choices about treatment \[[@CR24]\]. Doctor--patient discussions and programs to raise patient awareness will increase patients' knowledge about the individualization of treatment and may increase the number of women who take an active role in treatment decisions.

Patients with hormone-responsive breast cancer should be offered the opportunity of receiving the most effective endocrine therapy. Clinical evidence suggests that postmenopausal women should receive an AI rather than tamoxifen as their first option if tumor characteristics and individual side-effect profiles support this choice. Letrozole has consistently demonstrated superiority over tamoxifen in the metastatic and adjuvant treatment settings \[[@CR51], [@CR74], [@CR91], [@CR101]\]. As a result of its innovative clinical trial program \[[@CR51], [@CR74], [@CR101]\], letrozole is approved for use in postmenopausal women throughout the breast cancer care continuum \[[@CR137]\]. From the patient's perspective, the major benefits of letrozole are improving prospects for long-term survivorship ("cure") in the adjuvant setting and delaying progression and the need for chemotherapy in the metastatic setting.

Endocrine therapy is very effective, has a generally favorable safety profile, and adds to the efficacy of chemotherapy. However, a major challenge for both physicians and patients is ensuring compliance with long-term daily therapy. This may be a particular problem in the extended adjuvant setting, where the patient may face the prospect of life-long therapy. As patients no longer feel sick, it is understandable that they may forget to take a dose and gradually lose interest in continuing with the treatment. Letrozole is well-tolerated and, as with all AIs, the majority of adverse events are secondary to the suppression of estrogen. The most important adverse events from the patient's perspective are the "visible" ones, such as hot flushes, vaginal dryness, and arthralgias. To achieve optimal compliance, patients need to feel that physicians are taking their adverse events seriously and taking appropriate steps to alleviate any problems. Physicians who treat very few breast cancer patients may not have sufficient experience with AIs to satisfactorily manage individuals who are experiencing these adverse events.

Letrozole is likely to continue to play a major role in the management of breast cancer in all settings (see the paper in this supplement by Drs. Ellis and Ma, on Femara^®^ and the future). Considering its efficacy and favorable side-effect profile, it is the logical choice for inclusion in new regimens, including combinations with novel agents. As the future unfolds, the management of breast cancer is set for further change, and it is essential that patients are informed and educated so that they can actively participate in treatment decisions and thus derive the most benefit from treatment advances.

An erratum to this article can be found at <http://dx.doi.org/10.1007/s10549-007-9852-9>
